ENLV
Enlivex Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
0.36
▼ 0.00 (0.55%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.36
Prev close
0.36
Day high
0.37
Day low
0.34
Volume
409.34K
Market cap
$6.77M
P/E (TTM)
0.00
52W range
0.34 – 27.15
Day trading desk
Gap from prior close
-0.55%
Prior close 0.36
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
0.36 – 0.36
Position in range
—
—
ATR (14D)
0.09
26.09% of price
Prior day high
0.41
PDH
Prior day low
0.36
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 376.19K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-29.17%
-31.1%
1M
-69.09%
-70.2%
3M
-95.29%
-99.8%
6M
-97.28%
-115.5%
YTD
-96.78%
-111.0%
1Y
-97.86%
-114.3%
3Y
-98.57%
-180.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on ENLV open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
11.58M
Total on file
Fundamentals
Market cap$6.77M
Enterprise value$17.75M
Revenue (TTM)—
Gross profit—
EBITDA$-23.94M
Net income$3.19B
EPS (TTM)$494.00
Free cash flow$-3.74B
Total cash$5.52M
Total debt$17.54M
Book value / share$122.27
Shares outstanding19.91M
Float6.55M
Short % of float0.28%
Dividend yield0.00%
Beta (5Y)1.41
Valuation & profitability ratios
Trailing P/E0.00
Forward P/E-0.44
PEG ratio—
Price / sales—
Price / book0.00
EV / revenue—
EV / EBITDA-0.74
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity162.86%
Return on assets-0.62%
Debt / equity0.45
Current ratio119.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $9.20M | $10.62M | $19.01M | $18.69M | — | -13.4% |
| Selling, general & admin | $5.68M | $4.81M | $5.23M | $6.70M | — | +18.2% |
| Total operating expense | $15.00M | $14.93M | $25.15M | $25.80M | — | +0.5% |
| Operating income | -$15.00M | -$14.93M | -$25.15M | -$25.80M | — | -0.5% |
| Net interest income | $779.00K | $1.06M | $1.55M | $821.00K | — | -26.2% |
| Pre-tax income | $1.62B | -$15.01M | -$29.07M | -$31.06M | — | +10,877.8% |
| Tax provision | $382.65M | $0 | $0 | — | — | — |
| Net income | $1.24B | -$15.01M | -$29.07M | -$31.06M | — | +8,329.2% |
| Net income to common | $1.24B | -$15.01M | -$29.07M | -$31.06M | — | +8,329.2% |
| Basic EPS | — | -10.95 | -23.40 | -25.35 | -12.15 | — |
| Diluted EPS | — | -10.95 | -23.40 | -25.35 | -12.15 | — |
| EBIT | -$15.00M | -$14.93M | -$25.15M | -$25.80M | — | -0.5% |
| EBITDA | -$14.67M | -$14.39M | -$24.32M | -$25.02M | — | -2.0% |
| Basic shares | — | 1.37M | 1.24M | 1.23M | 1.19M | — |
| Diluted shares | — | 1.37M | 1.24M | 1.23M | 1.19M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.89M | $3.30M | $813.00K | $49.95M | — | -42.6% |
| Cash & short-term investments | $5.75M | $23.50M | $27.32M | $50.24M | — | -75.5% |
| Accounts receivable | — | — | — | — | $2.20M | — |
| Total current assets | $1.74B | $25.99M | $33.76M | $52.33M | — | +6,606.3% |
| Property, plant & equipment | $938.00K | $1.15M | $2.58M | $14.90M | — | -18.6% |
| Total assets | $2.33B | $27.69M | $36.83M | $67.64M | — | +8,304.7% |
| Total current liabilities | $9.02M | $3.80M | $6.06M | $6.61M | — | +137.5% |
| Total debt | $641.00K | $534.00K | $1.03M | $4.85M | — | +20.0% |
| Total liabilities | $392.05M | $4.10M | $6.75M | $10.80M | — | +9,466.9% |
| Retained earnings | $1.11B | -$127.11M | -$112.09M | -$83.03M | — | +972.0% |
| Shareholder equity | $1.93B | $23.59M | $30.08M | $56.84M | — | +8,102.8% |
| Working capital | $1.73B | $22.19M | $27.70M | $45.72M | — | +7,713.6% |
| Net tangible assets | $1.93B | $23.59M | $30.08M | $56.84M | — | +8,102.8% |
| Shares issued | 15.83M | 1.58M | 1.24M | 1.23M | — | +903.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.24B | -$15.01M | -$29.07M | -$31.06M | +8,329.2% |
| Depreciation & amortisation | $332.00K | $545.00K | $835.00K | $777.00K | -39.1% |
| Stock-based compensation | $1.78M | $2.06M | $1.95M | $2.71M | -13.7% |
| Change in working capital | $815.00K | -$1.22M | -$1.82M | $804.00K | +166.9% |
| Operating cash flow | -$10.42M | -$13.01M | -$23.52M | -$23.95M | +19.9% |
| Capital expenditure | -$68.00K | -$103.00K | -$236.00K | -$8.12M | +34.0% |
| Investing cash flow | -$1.32M | $9.06M | -$25.97M | $62.52M | -114.6% |
| Financing cash flow | $10.38M | $6.45M | $360.00K | $150.00K | +60.8% |
| Free cash flow | -$10.48M | -$13.11M | -$23.76M | -$32.08M | +20.0% |
| End cash position | $2.37M | $3.73M | $1.23M | $50.36M | -36.4% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $3.03M | $1.48M | $2.14M | $2.55M | +104.1% |
| Selling, general & admin | $2.72M | $1.07M | $937.00K | $954.00K | +153.6% |
| Total operating expense | $5.86M | $2.56M | $3.08M | $3.50M | +129.2% |
| Operating income | -$5.86M | -$2.56M | -$3.08M | -$3.50M | -129.2% |
| Net interest income | -$864.00K | $352.00K | $1.21M | $81.00K | -345.5% |
| Pre-tax income | $1.63B | -$2.21M | -$1.87M | -$3.45M | +73,827.8% |
| Net income | $1.24B | -$2.21M | -$1.87M | -$3.45M | +56,474.3% |
| Net income to common | $1.24B | -$2.21M | -$1.87M | -$3.45M | +56,474.3% |
| Basic EPS | — | -1.35 | -1.20 | -2.25 | — |
| Diluted EPS | — | -1.35 | -1.20 | -2.25 | — |
| EBIT | -$5.86M | -$2.56M | -$3.08M | -$3.50M | -129.2% |
| EBITDA | -$5.79M | -$2.48M | -$2.99M | -$3.41M | -133.6% |
| Basic shares | — | 1.60M | 1.59M | 1.58M | — |
| Diluted shares | — | 1.60M | 1.59M | 1.58M | — |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.89M | $4.08M | $1.89M | $2.05M | -53.6% |
| Cash & short-term investments | $5.75M | $18.20M | $19.51M | $20.55M | -68.4% |
| Total current assets | $1.74B | $19.50M | $21.32M | $22.65M | +8,840.3% |
| Property, plant & equipment | $938.00K | $1.08M | $923.00K | $1.07M | -13.2% |
| Total assets | $2.33B | $20.94M | $22.60M | $24.04M | +11,013.8% |
| Total current liabilities | $9.02M | $3.03M | $3.33M | $3.14M | +197.6% |
| Total debt | $641.00K | $701.00K | $480.00K | $503.00K | -8.6% |
| Total liabilities | $392.05M | $3.46M | $3.54M | $3.41M | +11,240.8% |
| Retained earnings | $1.11B | -$134.63M | -$132.43M | -$130.56M | +923.3% |
| Shareholder equity | $1.93B | $17.48M | $19.05M | $20.63M | +10,968.9% |
| Working capital | $1.73B | $16.47M | $18.00M | $19.50M | +10,431.1% |
| Net tangible assets | $1.93B | $17.48M | $19.05M | $20.63M | +10,968.9% |
| Shares issued | 15.83M | 1.62M | 1.59M | 1.59M | +877.2% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | $1.24B | -$2.21M | -$1.87M | -$3.45M | +56,474.3% |
| Depreciation & amortisation | $76.00K | $81.00K | $85.00K | $90.00K | -6.2% |
| Stock-based compensation | $915.00K | $280.00K | $295.00K | $293.00K | +226.8% |
| Change in working capital | $1.29M | -$176.00K | $172.00K | -$470.00K | +832.4% |
| Operating cash flow | -$2.63M | -$1.97M | -$1.20M | -$4.62M | -33.4% |
| Capital expenditure | -$8.00K | -$21.00K | -$7.00K | -$32.00K | +61.9% |
| Investing cash flow | -$9.38M | $3.81M | $1.07M | $3.17M | -345.9% |
| Financing cash flow | $9.83M | $352.00K | $0 | $197.00K | +2,693.2% |
| Free cash flow | -$2.63M | -$1.99M | -$1.21M | -$4.66M | -32.4% |
| End cash position | $2.37M | $4.55M | $2.35M | $2.48M | -47.8% |
Options analytics
Put / call volume
0.50
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
7.50
+2,104.6% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
+471.9%
Puts bid over calls
Call volume
14
Contracts, this expiry
Put volume
7
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
2.50
12 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.31 | 97.80 | +31,648.4% |
| Mar 2026 | -0.31 | — | — |
| Sep 2025 | -1.80 | -1.35 | +25.0% |
| Dec 2025 | -0.45 | -1.41 | -212.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.28 | 1 | $0 | 0.0% |
| Next quarter | -0.26 | 1 | $0 | 0.0% |
| Current year | -1.15 | 1 | $0 | 0.0% |
| Next year | -0.21 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$80.00
High target$80.00
Low target$80.00
Implied upside22122.22%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders68.82%
Held by institutions1.42%
Institutions holding25
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.49
-25.82% from price
SMA 20
0.66
-48.74% from price
SMA 50
1.27
-73.31% from price
SMA 100
5.04
-92.86% from price
SMA 200
9.79
-96.53% from price
EMA 12
0.52
-31.41% from price
EMA 26
0.88
-58.91% from price
EMA 50
1.95
-81.57% from price
RSI (14)
13.3
Oversold
MACD (12,26,9)
-0.35
Hist 0.04
ATR (14)
0.09
27.63% of price
Realised vol 30D
93.2%
Annualised
Bollinger upper
1.08
20, 2σ
Bollinger lower
0.24
20, 2σ
50 / 200 cross
Death
1.27 vs 9.79
Trend bias
Below 200
-96.53%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.04
More volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
93.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-98.1%
Peak to trough
Max drawdown 5Y
-99.8%
Peak to trough
ATR 14
0.09
27.63% of price
Beta (reported)
1.41
5Y monthly, from filing
Short interest
Shares short
48.20K
Prior 104.20K
Change vs prior
-53.7%
Shorts covering
% of float
0.28%
Normal
% of shares out
0.28%
Against total outstanding
Days to cover
0.2
Liquid
Float
6.55M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 12, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 24, 25 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Oct 29, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 26, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 12, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Sep 2, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 22, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 18, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 29, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 22, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateMar 6, 2019
Last split1:15
Split dateJul 9, 2026
SEC filings
Corporate Changes & Voting Matters
6-K/A · 2026-10-02
Corporate Changes & Voting Matters
6-K/A · 2026-10-01
Corporate Changes & Voting Matters
6-K · 2026-09-29
Corporate Changes & Voting Matters
6-K · 2026-09-25
Corporate Changes & Voting Matters
6-K · 2026-09-22
Corporate Changes & Voting Matters
6-K · 2026-08-11
Offering Registrations
F-3 · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-30
Headlines
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks · 36d ago
Enlivex Shares Plunge After $400 Million Private Placement Deal
MT Newswires · 71d ago
Top Midday Decliners
MT Newswires · 71d ago
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Zacks · 86d ago
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · 86d ago
Enlivex's Allocetra Receives FDA RMAT Designation for Knee Osteoarthritis
MT Newswires · 86d ago
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA
Investing.com · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.